Premature Rupture of Membrane Clinical Trial
Official title:
Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial
The objective of the study is to compare a new antibiotic protocol with the current prophylactic treatment in routine use and to evaluate obstetric and neonatal outcome: preterm labor, chorioamnionitis and early onset sepsis
Preterm premature rupture of membranes (PPROM) occurs in approximately 3% of all pregnancies
and is associated with approximately one-third of preterm births. The incidence of
chorioamnionitis in women with premature rupture of membranes (PROM) at < 27, 28 to 36, and
> 37weeks' gestation is 41, 15, and 2%, respectively. Intra-amniotic infection is usually
polymicrobial, comprised vaginal or enteric flora including aerobic and anaerobic bacteria
and atypical agents, such as Mycoplasma. Group B streptococcus (GBS) has been a frequent
pathogen. The American College of Obstetricians and Gynecologists approach to PPROM consists
of recommending induction of labor in all women > 34 weeks' gestation. In the absence of
intrauterine infection, placental abruption or non-reassuring fetal heart rate, management
of women with PPROM < 34 weeks consists of hospitalization from the time of diagnosis until
delivery, administration of antenatal corticosteroids, and a 7-day course of antibiotic
prophylactic therapy to prolong the latency period. Antibiotic therapy has been associated
with significant reductions in chorioamnionitis, deliveries within 48 hours, and early-onset
(within 3 days of delivery) neonatal sepsis (EOS). The antibiotic regimen in PPROM usually
consists of ampicillin intravenously for 48 hours, followed by oral amoxicillin for 5 days
(specifically targeting GBS), and a macrolide targeting atypical agents.
An increase in EOS due to gram negative Enterobacteriaceae have been reported lately with a
relative decrease in GBS related EOS . These data may have an impact on the antibiotic
regimen used for PPROM. The Local pathogens distribution in cases of EOS and their
antibiotic sensitivity profiles in Northern Israel have been explored in a multicenter study
There were 27 neonates diagnosed with EOS with positive blood cultures. Aerobic
Enterobacteriaceae accounted for 14 cases (52%) and group B streptococcus for 7 cases (26%).
Of the Escherichia coli and Klebsiella sp.,only 38% were sensitive to ampicillin. As a
result the most effective antibiotic protocol to cover those pathogens is required. The
purpose of the current study is to compare a new antibiotic protocol with the current
prophylactic treatment in use and to evaluate pregnancy and neonatal outcome.
The diagnosis of preterm premature rupture of membranes (PPROM) is clinical, and is based on
visualization of amniotic fluid in the vagina of a woman who presents with a history of
leaking fluid. Laboratory tests as "Amniosure" can be used to confirm the clinical diagnosis
when it is uncertain.
Women who meet the study criteria and have signed inform consent will be randomly divided in
two groups to receive prophylactic antibiotic treatment as follow:
1. I.V ampicillin 2 gram x4/d for 2 days followed by P.O moxypen 500 mgx3/d for additional
5 days+ P.O roxithromycin 150 mg*2/d for 7 days
2. I.V cefuroxime 750 mg*3/d for 2days followed by P.O cefuroxime 500 mgx2/d + P.O
roxithromycin 150 mg*2/d for 7 days
A course of corticosteroids will be given to all women participating in the study
Expectant management:
1. Vital signs *3/day
2. Uterine tenderness evaluation
3. Complete Blood Count + C-reactive protein every second day
4. Urine culture and GBS recto-vaginal swab
5. Fetal heart monitoring*6 /d
6. Sonography evaluation every 2-3 days
7. Vaginal swab once a week
8. Fetal movements follow up
Labor induction will be conducted at 34 weeks of gestation If chorioamnionitis is suspected
amniocentesis should be considered or expeditious delivery
;
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04100252 -
The Impact of Amniotic Fluid Index (AFI) on Maternal and Perinatal Outcomes in Pregnant Women With Preterm Premature Rupture of Membranes
|
||
Recruiting |
NCT04478942 -
PROMMO Trial: Oral Misoprostol vs IV Oxytocin
|
Early Phase 1 | |
Withdrawn |
NCT03172858 -
Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices
|
N/A | |
Not yet recruiting |
NCT05134688 -
Magnesium Sulphate in Premature Rupture of Membranes
|
Early Phase 1 | |
Not yet recruiting |
NCT03689062 -
Premature Rupture of Membranes at 34 to 37 Weeks' Gestation
|
N/A | |
Recruiting |
NCT06273891 -
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
|
Phase 3 | |
Recruiting |
NCT04237142 -
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)
|
N/A | |
Recruiting |
NCT04558996 -
Spanish Registry of Pregnant Women With COVID-19
|
||
Recruiting |
NCT04632017 -
Computerized Cardiotocography Monitoring of Fetuses With pPROM
|
||
Recruiting |
NCT03607929 -
HIDRATA Study: Efficacy of a Hydration Protocol in Nulliparous Women During Labor
|
N/A | |
Completed |
NCT03491826 -
Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)
|
||
Enrolling by invitation |
NCT04451109 -
Dilapan-S®: A Multicenter US E-registry
|
||
Recruiting |
NCT04143685 -
Labor Induction With Misoprostol Versus Oxytocin in Women With Premature Rupture of Membranes
|
N/A | |
Completed |
NCT03251898 -
Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
|
||
Completed |
NCT03106311 -
The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes
|
N/A |